• 1
    Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003; 9: 348359.
  • 2
    Gusberg SB, Runowiczl CD. Gynecologic cancers. In: HollebAI, FinkDJ, MurphyGP, editors. Textbook of Clinical Oncology. Atlanta: American Cancer Society, 1991; 481485.
  • 3
    Keys H, Gibbons SK. Optimal management of locally advanced cervical carcinoma. J Natl Cancer Inst Monogr. 1996; 8992.
  • 4
    Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001; 385: 781786.
  • 5
    Buda A, Fossati R, Colombo N, et al. Randomized trail of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005; 23: 41374146.
  • 6
    Long HJ3rdI, Bundy BN, Grendys ECJr., et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005; 23: 46264633.
  • 7
    Monk BJ, Huang HQ, Cella D, et al. Quality of life outcomes from a randomized Phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005; 23: 17.
  • 8
    Aaronson NK, Ahmedzai S, Bergman B, et al., for the EORTC Study Group on Quality of Life. The EORTC QLQ-C30. A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365375.
  • 9
    Sprangers MAG, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. Qual Life Res. 1998; 7: 291300.
  • 10
    Blazeby J, Sprangers M, Cull A, et al. EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules. 3rd ed. Brussels: EORTC Publications; 2001.
  • 11
    Cull A, Sprangers M, Bjordal K, et al. EORTC Quality of Life Group Translation Procedure. 2nd ed. Brussels: EORTC Publications; 2002.
  • 12
    Schwab DP. Construct validity in organization behavior. In: StawBM, CummingsLL, editors. Research in Organizational Behaviour. Greenwich: JAI Press, 1980: 343.
  • 13
    Fayers PM, Machin D. Multi-item scales. In: FayersPM, MachinD, editors. Quality of Life. Assessment, Analysis and Interpretation. West Sussex: John Wiley & Sons Ltd.; 2000: 7290.
  • 14
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, revised ed. New York: Academic Press; 1977.
  • 15
    Calhoun EA, Fishman DA, Lurain JR, et al. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004; 93: 164169.
  • 16
    Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO Stage 1B carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995; 32: 12891300.
  • 17
    Portenoy RK, Thaler H, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994; 30A: 13261336.
  • 18
    Steineck G, Bergmark K, Henningsohn L, et al. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol. 2002; 41: 244252.
  • 19
    Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC Publications; 2001.